A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

October 31, 2008

Conditions
Metastatic Melanoma
Interventions
GENETIC

VCL-IM01 (encoding IL-2) with Electroporation

IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).

Trial Locations (4)

36606

Location #2, Mobile

60068

Location #1, Chicago

80045

Location #3, Denver

07042

Location #4, Montclair

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Vical

INDUSTRY

NCT00223899 - A Trial to Evaluate the Safety of Intratumoral VCL-IM01 Followed by Electroporation in Metastatic Melanoma | Biotech Hunter | Biotech Hunter